Another false dawn for p53
Boehringer discontinues brigimadlin while others continue to struggle.
Boehringer discontinues brigimadlin while others continue to struggle.
Data on PMV’s p53 reactivator prompt a 26% selloff before their presentation, and 48% afterwards.